Logo

Fujirebio

Fujirebio Europe, Ohmx.bio Nab $873K Grant to Develop Clinical Third-Generation Sequencing Platform

The firms said that they will initially focus on the development of a portable, modular platform to detect highly polymorphic regions.

Morphotek, Fujirebio to Develop CA125 II Assay as CDx

The companies will validate and commercialize the assay as a companion diagnostic to identify best responders to Morphotek's investigational ovarian cancer treatment.

IP Roundup: Affymetrix, Nabsys, Ohio State U, Fujirebio Win US Patents
Premium

Affymetrix has been awarded

4,000-plus Patient Study Suggests ROCA Test Specific Enough for Use as Ovarian Cancer Screening Dx
Premium

A longitudinal study of the Risk of Ovarian Cancer Algorithm has found that the algorithm in combination with transvaginal ultrasound offers suitable specificity and positive predictive value for it to be used as an ovarian cancer screening test in post-menopausal women.

UPDATE: Vermillion Repays Quest $5.9M, Ending Companies' Credit Agreement
Premium

This article has been updated from a version posted Oct. 12 to include additional information.
Aug 31, 2012

Healthlinx Inks Deal to Sell OvPlex Dx to San Diego-Based Startup Mane Cancer Diagnostics
Premium

Oct 14, 2011

Is Healthlinx Eyeing Purchase of Correlogic's Assets as Part of Move into US Cancer Dx Market?
Premium

Sep 16, 2011

New Data Demonstrates Increased Sensitivity When Vermillion's OVA1 is Used with Imaging
Premium

Sep 9, 2011

FDA Grants Fujirebio 510(k) Approval for ROMA Ovarian Cancer Dx, Potential Rival to Vermillion's OVA1
Premium

Aug 5, 2011

Vermillion Performs 3,920 OVA1 Tests in Q2, But Revenues Fall 9 Percent on Drop in Licensing Income
Premium

Jul 29, 2009

Abbott, Fujirebio Co-Developing HE4/CA125 Dx to Improve Early Ovarian Cancer Detection
Premium

May 4, 2009

BD, Fujirebio Partner on Cancer Dx Assays

Mar 5, 2009

EC Gives New Consortium $3.8M to Develop High-throughput Technology for Biomarker Detection
Premium

Feb 19, 2009

Industry Briefs: Feb 19, 2009
Premium

Feb 17, 2009

BioArray Briefs: 2009.02.17
Premium

Feb 16, 2009

European Consortium Awarded Nearly $4M to Develop Plasma Biomarker Discovery Platform

Breaking News
The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.